Clinical predictor of survival following docetaxel-based chemotherapy - Abstract

Prostate cancer (PCa) is the most common type of cancer in males in the USA and the incidence is increasing.

For castration-resistant PCa (CRPC), previous studies have identified docetaxel-based chemotherapy as the first-line therapy. In the present study, the efficacy of docetaxel-based chemotherapy was investigated in a population of patients with CRPC. This study included 26 individuals (mean age, 73 years) with CRPC who were patients between July 2007 and October 2012 at the Kaohsiung Medical University Hospital (Kaohsiung, Taiwan). The regimen consisted of intravenous docetaxel (70 mg/m2) once every four weeks plus oral prednisolone (5 mg) twice daily for five days. Prostate-specific antigen (PSA) response (defined as a PSA decrease of >50% over four weeks), time to PSA progression, PCa-specific survival and overall survival (OS) were evaluated. For these 26 patients, the mean PSA level prior to chemotherapy treatment was 335.58 ng/ml. During follow-up, the average number of cycles of chemotherapy was approximately seven and 15 patients (58%) achieved a PSA response. PSA response was found to significantly correlate with OS and PCa-specific survival (P=0.014 and P=0.028, respectively). The mean value of the PSA nadir level was 89.97 ng/ml and time to PSA nadir was five months. The most common adverse event was leucopenia, which affected 88% of the patients. The results indicated that the length of time to PSA nadir and the occurrence of leucopenia may impact the PSA response. The docetaxel-based chemotherapy was a feasible and effective treatment regimen in patients with CRPC. However, the occurrence of adverse events, particularly the high incidence of leucopenia, may be cause for concern.

Written by:
Lee HY, Wu WJ, Huang CH, Chou YH, Huang CN, Lee YC, Yang KF, Lee MH, Huang SP.   Are you the author?
Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan, R.O.C; Department of Urology, Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung 812, Taiwan, R.O.C; Department of Urology, College of Medicine, Kaohsiung Medical University Kaohsiung, Kaohsiung 807, Taiwan, R.O.C.

Reference: Oncol Lett. 2014 Oct;8(4):1788-1792.
doi: 10.3892/ol.2014.2349

PubMed Abstract
PMID: 25202411 Prostate Cancer Section